Navigation Links
Paradigm Announces Molecular Profiling Collaboration for Study of Altiratinib In Genomically Defined Cancer Patients
Date:8/19/2015

ANN ARBOR, Mich. and PHOENIX, Aug. 19, 2015 /PRNewswire-USNewswire/ -- Paradigm today announced a pharmaceutical services relationship with Deciphera Pharmaceuticals for a phase I clinical study of Altiratinib in molecularly defined cancers driven by either MET or TRK genomic alterations including lung cancer, gastric cancer, renal cancer, and glioblastoma multiforme (GBM).

Paradigm will use its Paradigm Cancer Diagnostic (PCDx) panel's advanced molecular capabilities to characterize patient tissue samples from clinical trials to better predict which patients may be sensitive or resistant to Deciphera's Altiratinib, a MET/TIE2/VEGFR2/TRK (A,B,C) kinase inhibitor, which has been granted an Orphan Drug Designation for GBM by the FDA.  PCDX is also broadly available to assist cancer patients and their oncologists find actionable FDA approved therapies.

Robert J. Penny MD, PhD, CEO of Paradigm noted "Paradigm is successfully working with leading biopharmaceutical companies to craft personalized interrogations for clinical trial selection and is providing accelerated translational treatment decisions in patient care as part of our PCDx panel."

About PARADIGM

Paradigm is a molecular information corporation established to bring cutting-edge diagnostics to cancer patients and industry by providing information about the genomic makeup of the patient's cancer and potential therapies based on the specific characterization of the patient's tumor that can impact the patient's course of treatment. Paradigm's Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visit http://www.paradigmdx.org.

Photo - http://photos.prnewswire.com/prnh/20150818/259483
Logo - http://photos.prnewswire.com/prnh/20140819/137529


'/>"/>
SOURCE Paradigm
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
2. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
3. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
4. Study Published in Nature Biotechnology Demonstrates Ability of Modernas Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
5. RNA Aptamers: A New Paradigm in Cancer Diagnosis and Treatment, New Life Science Webinar Hosted by Xtalks
6. Stanford study could lead to paradigm shift in organic solar cell research
7. Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information
8. Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics
9. Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study
10. Paradigm CEO Dr. Robert Penny Presents Keynote Address at 2015 ISBER Conference
11. Paradigm and TME Research To Launch Precision Medicine Breast Cancer Registry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/10/2019)... ... April 10, 2019 , ... ... locked into multiple agreements to help companies advance their innovations to clinical ... ranging from synthetic biology companies that are gene editing therapeutic cells for ...
(Date:4/8/2019)... and BOSTON (PRWEB) , ... April 08, 2019 ... ... cloud-based enterprise-class unified communications and collaboration solutions, announced today the launch of their ... to an unprecedented range of business and contact-orientated applications while using CT Cloud ...
(Date:3/29/2019)... ... March 28, 2019 , ... Specific Diagnostics announced today ... with a second stage of funding for Specific’s Reveal™ rapid antibiotic susceptibility test ... of the $1.7 million already awarded by CARB-X. The additional $1.7M will enable ...
(Date:3/23/2019)... ... March 22, 2019 , ... Tosoh Bioscience LLC ... (MALS) detector , offering a revolutionary approach for the measurement of molecular weight ... A novel optical design, a unique cell-block assembly, and a new calculation methodology ...
Breaking Biology Technology:
(Date:4/18/2019)... CREEK, Calif. (PRWEB) , ... April 18, 2019 ... ... for the healthcare industry, today announced the launch of mSource® AI Contract Text ... extract deep knowledge of Medpricer customers’ supplier contracts, truly optimizing purchased services spend ...
(Date:4/16/2019)... ... April 16, 2019 , ... HealthLink ... opening of its new medical device facility on Friday, April 12. Headquartered in ... TN the new facility includes 108,500 square feet and houses 32 employees enabling ...
(Date:4/16/2019)... ... April 16, 2019 , ... The International Society ... The 2019 ISPE Biopharmaceutical Manufacturing Conference , on 18–20 June and The ... one of the most influential bio hubs, Boston, Massachusetts USA, these concurrent events ...
Breaking Biology News(10 mins):